Duke Researchers Contribute to Study Uncovering Alzheimer's Clues

A new study has identified two naturally occurring molecules in the blood that may offer critical insights into Alzheimer's disease, particularly its progression in women.

The findings, published in Molecular Psychiatry, suggest these molecules – acetyl-L-carnitine and free carnitine – could serve as biomarkers for diagnosing and tracking the disease.

Researchers from Duke University were part of the international team that contributed to this work, which may lead to less invasive diagnostic methods and new avenues for treatment.

What the Study Found

The study examined blood samples from men and women with varying levels of cognitive impairment. It found that blood levels of acetyl-L-carnitine and free carnitine declined steadily in women as cognitive symptoms worsened – from mild memory issues to more advanced Alzheimer’s stages. For men, declines were noted only in acetyl-L-carnitine, suggesting a potential biological explanation for why Alzheimer’s disproportionately affects women.

The research also revealed that these molecules track closely with amyloid beta and tau proteins, hallmark indicators of Alzheimer’s severity. This connection allowed researchers to identify disease progression with 93% accuracy when combining data from the molecules and protein levels.

Potential Implications

If confirmed by further studies, the findings could lead to the development of a blood test for Alzheimer’s disease. Currently, diagnosing the condition often involves spinal taps or brain imaging, both of which can be costly and invasive. A simple blood test could make diagnosis more accessible and allow for earlier intervention.

Additionally, the study raises questions about whether targeting the molecular pathways involved in acetyl-L-carnitine and free carnitine production could open the door to new treatments. These molecules play a role in brain energy metabolism and nerve cell repair, which are essential processes affected by Alzheimer’s.

The Role of Duke University

Duke University researchers James Beasley and Sarah Young contributed to this study alongside colleagues from NYU Langone Health and institutions in Brazil and California. Their participation underscores the university’s ongoing efforts to advance research on neurodegenerative diseases.

What’s Next?

While promising, these findings are just a starting point. Researchers aim to explore the molecular pathways behind acetyl-L-carnitine and free carnitine declines, particularly in women, and how these changes affect brain function. They also plan to investigate whether these biomarkers can reliably predict the effectiveness of treatments aimed at delaying or preventing Alzheimer’s.

Why This Matters

For South Durham residents, particularly those with loved ones at risk for Alzheimer’s, this research offers a potential step forward in making diagnosis and treatment more accessible. With women making up the majority of Alzheimer’s patients, the study’s focus on sex differences could also help address a long-standing gap in understanding the disease.

Although further research is needed before these findings can translate to everyday medical practice, they highlight a shift toward earlier, less invasive methods of managing Alzheimer’s—something that could make a significant difference for patients and their families.

For more information on Alzheimer’s support or research participation opportunities in the Triangle, check out local organizations such as the Alzheimer’s Association and Duke University’s Alzheimer’s programs.

Southpoint Access, your ultra-local neighborhood news source in South Durham, is made possible by support from readers like you, as well as our sponsors. Current sponsors include: